Therapeutic Response

PD-L1 >= 5% status confers therapeutic sensitivity to Atezolizumab in patients with Bladder Urothelial Carcinoma.

Statements

Source and description
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumors have a PD-L1 expression >= 5%.
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible, and whose tumors have PD-L1 expression >= 5%.
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible and whose tumors have PD-L1 expression >= 5%.